Chattem Looks To Tech: ‘Cool’ New Products Not What They Used To Be
This article was originally published in The Tan Sheet
Executive Summary
Chattem is focused on acquiring technology rather than new brands, the firm said during a report on fourth-quarter and fiscal year 2005 (ended Nov. 30)
You may also be interested in...
Chattem
Brands targeted as acquisition candidates likely would be $10 mil.-$50 mil. businesses in the OTC category that are advertising sensitive, Chattem notes during Deutsche Bank Securities Small Cap Growth Conference Feb. 16. The firm states it would stay out of "huge categories with a lot of bigger players." Acquisitions, however, are not a priority for Chattem, as it currently is more interested in licensing new technology for use in skin care and pain relief than buying standalone brands (1"The Tan Sheet" Feb. 6, 2006, p. 6)...
Pfizer Eyes Consumer Unit Spin-Off Or Sale Price North of $10 Bil.
Pfizer has "no interest" in separately divesting individual products from its consumer division, CEO Hank McKinnell said during a Feb. 10 analysts presentation
New Product Mix, Raw Materials Costs Expected To Erode Chattem Margins
Chattem expects gross profit margin to drop 4% in 2006, company CFO Rick Moss announced Nov. 8